Abstract:The Ras association domain family 1 isoform A (RASSF1A) is a tumor suppressor whose inactivation is implicated in the development of many human cancers, including breast carcinomas. Little is known about the tumor-suppressive function of RASSF1A in breast tissue and whether its inactivation is mechanistically involved in the initiation and progression of breast tumors. Here, we show that RASSF1A inhibits breast cancer growth in vivo, and suppresses estrogen receptor (ERα) expression and function. Reconstitution of RASSF1A in MCF7 cells led to decreased ERα levels and reduced sensitivity to estrogen (E2). Concomitantly, we observed decreased expression of Id1 as well as the E2-responsive genes Bcl-2 and c-Myc that cooperatively contribute to the immortalization and transformation of breast epithelial cells. This downregulation was associated with induction of cell-cycle arrest and senescence that constitute early barriers to cancer initiation and progression. Knockdown of ERα showed that downregulation of ERα suffices to increase senescence and inhibit expression of Bcl-2, c-Myc and Id1. However, enforced expression of ERα only partially rescued RASSF1A-mediated growth inhibition and senescence, suggesting that suppression of ERα expression and activity is not the only mechanism by which RASSF1A inhibits growth and survival of breast cancer cells. Ectopic expression of Bcl-2, c-Myc and Id1 had little or no effect on RASSF1A-mediated growth arrest, indicating that RASSF1A acts dominantly over these oncogenes. Mechanistically, RASSF1A was found to suppress ERα expression through Akt1. It also transiently inhibited ERα-induced Ras-MAPK activity after exposure of cells to E2. Together, our data show that RASSF1A acts as a tumor suppressor in ERα+ mammary epithelial cells, in part through inhibiting ERα expression and activity. These findings suggest that RASSF1A has a key role in suppressing the transformation of human breast epithelial cells and ERα+ breast cancer initiation.

RASSF1A disrupts the NOTCH signaling axis via SNURF/RNF4‐mediated ubiquitination of HES1

Human Homolog of Drosophila Hairy and Enhancer of Split 1, Hes1, Negatively Regulates Δ-Catenin (CTNND2) Expression in Cooperation with E2F1 in Prostate Cancer

RASSF1A Promotes ATM Signaling and RASSF1A Methylation is a Synthetic Lethal Marker for ATR Inhibitors.

High Frequency of HES1 Loss in Colorectal Adenocarcinomas with RAS/BRAF Mutations

RASSF1A Suppresses Melanoma Development by Modulating Apoptosis and Cell‐cycle Progression

RASSF1C oncogene elicits amoeboid invasion, cancer stemness, and extracellular vesicle release via a SRC/Rho axis

Ras-association Domain Family 10 Acts As a Novel Tumor Suppressor Through Modulating MMP2 in Hepatocarcinoma

Identification and targeting of a HES1-YAP1-CDKN1C functional interaction in fusion-negative rhabdomyosarcoma

Decreased Expression of RASSF1A and Up-Regulation of RASSF1C is Associated with Esophageal Squamous Cell Carcinoma

Analysis of Liver Tumor-Prone Mouse Models of the Hippo Kinase Scaffold Proteins RASSF1A and SAV1.

Small GTPase RhoE/Rnd3 is a critical regulator of Notch1 signaling.

RIP140 regulates transcription factor HES1 oscillatory expression and mitogenic activity in colon cancer cells

RASSF1A Suppresses Estrogen-Dependent Breast Cancer Cell Growth through Inhibition of the Yes-Associated Protein 1 (YAP1), Inhibition of the Forkhead Box Protein M1 (FOXM1), and Activation of Forkhead Box Transcription Factor 3A (FOXO3A)

The Tumor Suppressor RASSF 1 A Prevents Dephosphorylation of the Mammalian STE 20-Like Kinases MST 1 and MST 2 *

RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development

A “janus” Face of the RASSF4 Signal in Cell Fate

Decreased Expression of EZH2 Reactivates RASSF2A by Reversal of Promoter Methylation in Breast Cancer Cells

Up-regulated transcriptional regulators in mutant RAS gene signatures: a time-resolved multi-omics study in generic epithelial cell models

ZNF281/Zfp281 is a Target of Mir‐1 and Counteracts Muscle Differentiation

ASPM stabilizes the NOTCH intracellular domain 1 and promotes oncogenesis by blocking FBXW7 binding in hepatocellular carcinoma cells

HES1 Promotes Metastasis and Predicts Poor Survival in Patients with Colorectal Cancer